AstraZeneca PLC — Major Shareholding Notification 2021

Jul 27, 2021

SC 13G 1 tm2123282d1_sc13g.htm SC 13G

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. )*

Aridis Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

040334104

(CUSIP Number)

July 20, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

CUSIP No. 040334104 — 1.	Name of Reporting Person AstraZeneca PLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)	¨
	(b)	x (Joint filers)
3.	SEC Use Only
4.	Citizenship or Place of Organization United Kingdom
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 884,956 shares 1
	6.	Shared Voting Power 0 shares
	7.	Sole Dispositive Power 884,956 shares 2
	8.	Shared Dispositive Power 0 shares
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 884,956 shares 3
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.3% 4
12.	Type of Reporting Person (See Instructions) CO

Field: Rule-Page

Field: /Rule-Page

1 Represents shares directly held by MedImmune Limited, a wholly-owned indirect subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over the shares.

2 See footnote 1.

3 See footnote 1.

4 The percentage ownership was calculated based on a denominator which is the sum of (i) 11,232,921 shares of the issuer’s common stock outstanding as of April 30, 2021, as reported in the issuer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (the “Form 10-Q”) filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2021 and (ii) the 884,956 shares of the issuer’s common stock held by the Reporting Persons.

Field: Page; Sequence: 2; Options: NewSection; Value: 2

Page Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence of 6

Field: /Page

CUSIP No. 040334104 — 1.	Name of Reporting Person MedImmune Limited
2.	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)	¨
	(b)	x (Joint filers)
3.	SEC Use Only
4.	Citizenship or Place of Organization United Kingdom
Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 884,956 shares 5
	6.	Shared Voting Power 0 shares
	7.	Sole Dispositive Power 884,956 shares 6
	8.	Shared Dispositive Power 0 shares
9.	Aggregate
Amount Beneficially Owned by Each Reporting Person 884,956 shares 7
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.3% 8
12.	Type of Reporting Person (See Instructions) CO

Field: Rule-Page

Field: /Rule-Page

5 See footnote 1.

6 See footnote 1.

7 See footnote 1.

8 See footnote 4.

Field: Page; Sequence: 3; Value: 2

Page Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence of 6

Field: /Page

Item 1.	(a)	Name of Issuer Aridis Pharmaceuticals, Inc.
	(b)	Address
of Issuer’s Principal Executive Offices 983 University Avenue Building B Los Gatos, California 95032
Item 2.
	(a)	Name of Person Filing See response to 2(c)
	(b)	Address of Principal Business Office or, if none, Residence See response to 2(c)
	(c)	Citizenship This statement is filed on behalf of: AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Citizenship: United Kingdom MedImmune Limited Milstein Building Granta Park Cambridge CB21 6GH United Kingdom Citizenship: United Kingdom
	(d)	Title of Class of Securities Common Stock, par value $0.0001 per share
	(e)	CUSIP Number 040334104
Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	(a)	¨	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
	(b)	¨	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
	(c)	¨	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d)	¨	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
	(e)	¨	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
	(f)	¨	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
	(g)	¨	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
	(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	¨	A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
	(k)	¨	Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing
as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____

Field: Page; Sequence: 4; Value: 2

Page Field: Sequence; Type: Arabic; Name: PageNo 4 Field: /Sequence of 6

Field: /Page

Item 4.	Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount beneficially owned: 884,956 shares
	(b)	Percent of class: 7.3%. The percentage ownership was calculated based on a denominator
which is the sum of (i) 11,232,921 shares of the issuer’s common stock outstanding as of April 30, 2021, as reported in
the Form 10-Q filed with the SEC on May 11, 2021 and (ii) the 884,956 shares of the issuer’s common stock held by
the Reporting Persons.
	(c)	Number of shares as to which the person has:
		(i)	Sole power to vote or to direct the vote: AstraZeneca PLC: 884,956 shares MedImmune
Limited: 884,956 shares
		(ii)	Shared power to vote or to direct the vote: AstraZeneca PLC: 0 shares MedImmune
Limited: 0 shares
		(iii)	Sole power to dispose or to direct the disposition of: AstraZeneca PLC: 884,956 shares MedImmune
Limited: 884,956 shares
		(iv)	Shared power to dispose or to direct the disposition of: AstraZeneca PLC: 0 shares MedImmune
Limited: 0 shares
MedImmune Limited, a wholly-owned indirect subsidiary of AstraZeneca
PLC, is the direct record holder of all 884,956 shares reported herein. Each of MedImmune Limited and AstraZeneca PLC may be deemed to
have sole voting and dispositive power with respect to such shares.
Item 5.	Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ¨
Item 6.	Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
Not applicable.
Item 8.	Identification and Classification of Members of the Group
Not applicable.
Item 9.	Notice of Dissolution of Group
Not applicable.
Item 10.	Certifications
Not applicable.

Material Filed as Exhibits

Exhibit 99 Joint Filing Agreement between AstraZeneca PLC and MedImmune Limited

Field: Page; Sequence: 5; Value: 2

Page Field: Sequence; Type: Arabic; Name: PageNo 5 Field: /Sequence of 6

Field: /Page

Signatures

After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

July 27, 2021

AstraZeneca PLC /s/ Adrian Kemp
Signature
Adrian Kemp, Company Secretary
Name/Title

MedImmune Limited /s/ Matthew Bowden
Signature
Matthew Bowden, Director
Name/Title

Attention : Intentional misstatements or omissions of fact constitute federal criminal violations ( see 18 U.S.C. 1001).

Field: Page; Sequence: 6; Options: Last

Page Field: Sequence; Type: Arabic; Name: PageNo 6 Field: /Sequence of 6

Field: /Page